

Indices	Value	Pts	Chg (%)
SENSEX	48440.1	(740.2)	-1.51
NIFTY	14324.9	(224.5)	-1.54
SGX NIFTY*	14565.5	237.0	1.65
DOW Jones	32619.5	199.4	0.62
S&P	3909.5	20.4	0.52
Nasdaq	12977.7	15.8	0.12
FTSE	6674.8	(38.1)	-0.57
CAC	5952.4	5.1	0.09
DAX	14621.4	11.0	0.08
Shanghai Composite*	4966.3	39.9	0.81
Nikkei*	29145.1	415.2	1.45
Hang Seng*	28074.5	174.9	0.63

\*As at 8.00 am

Most Active Call & Put			
Symbol	Strike Price	OI (000)	Chg (%)
NIFTY	15000CE	29833	39.4
NIFTY	14000PE	27990	24.6

Commodity	Price	Pts	Chg (%)
NYMEX Crude (USD)	59.1	0.5	0.9
Brent Crude (USD)	62.3	0.4	0.6
Gold (USD)	1726.9	-0.4	0.0
Silver (USD)	25.16	0.11	0.45
Copper (USD)	400.65	2.85	0.72
Cotton (USD)	77.51	-0.93	-1.19

Currency	Value	Pts	Chg (%)
USD/Rupee	72.59	-0.07	-0.09
Euro/Rupee	85.53	-0.07	-0.09
Pound/Rupee	99.85	0.03	0.03
USD/Euro	1.18	0.00	0.01
Dollar Index	92.78	-0.07	-0.07

Indicators	Value	Pts	Chg (%)
CBOE VIX	19.8	-1.4	6.6
India VIX	22.7	0.2	1.1

Indicators	Value	Bps chg
India 10-Yr Yield	6.13	-2.1
US 10-Yr Yield	1.63	-5.0

Trade Statistics	BSE	NSE	F & O
Turnover (INR Crs)	4021	57860	9513616
Advance (Nos)	4	5	NA
Declines (Nos)	26	45	NA
Unchanged	0	0	NA

## Market Summary

Tracking firm cues from global peers, Indian markets looked set to bounceback after two-days of bear hammering and kick off the April F&O series on a gap-up note. Nifty futures on the Singapore Exchange traded 1.65 per cent higher at 14,565.

In the overnight session, the US market ended higher as investors bought stocks likely to do well in the recovery after US President Joe Biden doubled his target for administering Covid-19 vaccines. The Dow Jones Industrial Average rose 0.62%, the S&P 500 gained 0.52% and the Nasdaq Composite added 0.12%.

Asian stocks followed their US peers higher and were trading on an upbeat note with Japan's Nikkei 225 Index up 1.7% and Australia's S&P/ASX 200 Index up 0.6%. S&P500 and Nasdaq futures also traded higher by 0.30% each.

Now, a look at the stock-specific triggers that are likely to guide the market today: Shares of Kalyan Jewellers and Suroday Small Finance Bank will list at the bourses today. The IPO of Suryoday SFB was subscribed 2.37 times while that of Kalyan Jewellers was subscribed 2.61 times.

French company Groupe Atlantic would invest Rs 68.3 crore in Somany Home Innovation Limited (SHIL) for 50 per cent stake in its water heater business, as per a regulatory filing.

Promoters Jio Content Distribution Holdings, Jio Internet Distribution Holdings and Jio Cable and Broadband Holdings to sell up to 33.79 crore equity shares, representing 19.09% of the total equity share capital of Hathway Cable, through an Offer for Sale. The OFS opens for non-retail investors today and for retail investors on March 30.

## Macro News

### House that: Anarock says home sales up 29% in March qtr, JLL finds down 7%

Two property consultants on Thursday published reports that gave opposite numbers on home sales in India in the March quarter of calendar year 2020. Sales in top seven cities went up 29 per cent on a yearly basis, said Anarock Property Consultants. As many as 58,290 homes were sold in quarter one of 2021 compared to 45,200 units in Q1 of 2020. Mumbai Metropolitan Region (MMR) and Pune together accounted for 53 per cent of the sales. MMR sales increased by 46 per cent annually and Pune by 47 per cent, said Anarock. With about 8,670 units sold, Bengaluru was the only city not to record a major yearly change in total numbers this quarter.

### Second Covid wave unlikely to derail India's growth: RBI Governor

India's economic growth is unlikely to get much of a hit due to the second wave of Covid-19, RBI governor Shaktikanta Das said on Thursday. "My understanding and our preliminary analysis show that the growth rate in next year, that is 10.5 per cent (RBI forecast for FY22), which we had given in the policy would not require, I repeat, would not require a downward revision," Das said. A renewed surge of Covid cases in many parts of the country is a matter of concern, but this time around, vaccinations are taking place, and overall, the people are more used to the Covid protocol.

### Sebi to set up fund to buy stressed corporate bonds: FM Sitharaman

The Securities and Exchange Board of India will set up Corporate Debt Market Development Fund (CDMDF) to provide liquidity to mutual funds and other participating institutional investors in the corporate bond market, Finance Minister Nirmala Sitharaman said.

Institutional Activity	Cash	
	25-March-21	24-March-21
<b>FIIs (INR Crs)</b>		
Buy	6669.49	5577.51
Sell	10053.09	7529.41
Net	(3383.60)	(1951.90)
<b>DII (INR Crs)</b>		
Buy	7823.37	5581.34
Sell	5555.68	4968.54
Net	2267.69	612.80

FII Derivative Statistics			
Particulars	Buy (INR Crs)	Sell (INR Crs)	OI (Nos)
INDEX FUTURES	7926.47	9603.38	140045
INDEX OPTIONS	512596.00	509578.57	1156318
STOCK FUTURES	26171.64	26898.25	1101151
STOCK OPTIONS	10337.12	10263.15	146147
Total	557031.23	556343.35	

Gainers & Losers	Price	Chg (%)
<b>Gainers (INR)</b>		
TATASTEEL	722.95	2.87
DRREDDY	4384.50	0.78
ICICIBANK	570.60	0.55
HDFC	2478.00	0.50
LT	1374.00	0.35
<b>Losers (INR)</b>		
IOC	90.75	-4.02
MARUTI	6792.00	-3.88
COALINDIA	127.80	-3.40
BHARTIARTL	507.20	-3.14
HINDUNILVR	2248.95	-3.00

Sectoral Performance	Value	Pts	Chg (%)
S&P BSE Small Cap	20062.06	-378.86	-1.85
S&P BSE Mid-Cap	19643.89	-446.64	-2.22
S&P BSE Auto	21790.67	-627.54	-2.80
S&P BSE BANKEX	37201.49	-289.19	-0.77
S&P BSE Capital Goods	20648.60	-218.63	-1.05
S&P BSE FMCG	12246.98	-297.84	-2.37
S&P BSE Healthcare	20608.45	-239.41	-1.15
S&P BSE IT	25742.06	-467.21	-1.78
S&P BSE Metals	13467.62	-7.20	-0.05
S&P Oil & Gas	14555.72	-378.84	-2.54

## Key News

### Jubilant Foodworks doubles its QSR target market with Popeyes tie-up

Jubilant Foodworks' latest tie-up to launch the Popeyes Restaurants in India will expand its food portfolio and increase the addressable market in the fast growing western quick service restaurant or QSR market. Popeyes Restaurants is the world's third largest QSR chicken brand. The QSR chicken market size run by larger chains is estimated at around Rs 3,000 crore, in which KFC dominates controlling about two thirds of the market, estimates Emkay Research. Westlife Development (McDonald's) recently ventured into this space in South India.

### GoAir plans Rs 2,500-cr IPO early FY22; may file preliminary papers in Apr

Wadia group-owned GoAir plans to come out with a Rs 2,500 crore-initial share sale early next fiscal, according to sources. The no-frills airline has been working on expansion plans and an Initial Public Offer (IPO) will help in raising funds. In recent months, many companies have hit the capital market with their IPOs amid business activities slowly normalising after the pandemic blow. The carrier, which started operations in 2005, has been contemplating about going public in the last couple of years. The airline, which has also been witnessing frequent churns in the top management, could not come out with the IPO on a few occasions earlier.

### Shriram Transport declares second dividend of Rs 6 per share for FY21

Shriram Transport Finance Company on Thursday said its board has declared a second interim dividend of Rs 6 per share for 2020-21. This is in addition to the first dividend of Rs 6 per share declared by the board on October 29, 2020 and paid to the eligible shareholders on November 26, Shriram Transport said in a regulatory filing. "The board of directors of the company at their meeting held on March 25, 2021 approved declaration of second interim dividend of Rs 6 per equity share of Rs 10 each fully paid up (60 per cent) for the financial year 2020-21," the company said. It said it has fixed April 6 as the record date for payment of the second interim dividend, subject to deduction of tax at source, to eligible shareholders.

### Mukesh Ambani sees a 'tsunami of opportunities' for entrepreneurs

With the Indian Prime Minister Narendra Modi advocating a greater role for the private sector coupled with India's access to high end technology, Mukesh Ambani, Chairman and MD of Reliance Industries sees a "tsunami of opportunities" for young Indian entrepreneurs. Addressing the virtual 22nd Entrepreneur of the Year – India (EOY) 2020 Awards ceremony, Ambani said India should welcome Modi's initiative for a greater role for the private sector India's future development. Ambani said India now has the revolutionary power of new technologies to transform the economy. "Small, medium and big businesses have once-in-a-lifetime opportunity to meet the needs and aspirations of 1.3 billion people for good quality of life. We have the potential in the coming decades to be among top three economies of the world," Ambani said.

### Zydus Cadila receives tentative nod from USFDA to market two HIV drugs

Zydus Cadila on Thursday said it has received a tentative nod from the US health regulator to market Emtricitabine and Tenofovir Disoproxil Fumarate tablets used for controlling human immunodeficiency virus (HIV) infection, in America. The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate tablets 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg, Zydus Cadila said in a statement. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ Ahmedabad, it added. The tablets are used with other HIV medications to help control HIV infection, Zydus Cadila said.



**Analyst Certification of Independence:** The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking Company having membership of NSE, BSE & MSEI for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. [www.spasecurities.com](http://www.spasecurities.com).

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. Vide SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

**General Disclosures:** This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.

The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com) and <http://economictimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

**Disclaimers in respect of jurisdiction:** This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of SPA Securities.

List of Associates as per SEBI (Research Analyst) Regulations, 2014

Statements on ownership and material conflicts of interest, compensation - SPA and Associates

Disclosure of interest statement	Yes/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month. Immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
<ul style="list-style-type: none"> <li>Managing/co-managing public offering of securities</li> <li>Investment banking/merchant banking/brokerage services</li> <li>products or services other than those above</li> <li>in connection with research report</li> </ul>	No
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company;	No

For statements on ownership and material conflicts of interest, compensation, etc. for individual Research Analyst(s), please refer to each specific research report.

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

**SPA GLOBAL PRIVATE LIMITED**  
 Mutual Fund Advisor  
 AMFI Reg. No. 90796

SPA SECURITIES LTD	SEBI REG. NOS.
NSE Cash	INZ000241036
NSE Future & Option	INZ000241036
NSE Currency Derivatives	INZ000241036
BSE Cash	INZ000241036
BSE Currency Derivatives	INZ000241036
MSEI Cash	INZ000241036
MSEI Future & Option	INZ000241036
MSEI Currency Derivatives	INZ000241036
Mutual Fund	ARN 77388
CDSL DP	IN-DP-CDSL-485-2008
NSDL DP	IN-DP-NSDL-316-2009
SEBI Research Analyst	INH100002615
Merchant Banker	INM000012740